Photocure provides strategic update
· Following non-conclusive partnering discussions, the company will assess further strategic alternatives for Cevira and Visonac · Company still to focus on urology franchise, with continued commitment to driving growth in United States Oslo, Norway, 5 April 2017: Photocure ASA (Photocure, OSE: PHO), today announces that the company will assess further strategic alternatives for its non-urology assets, Cevira and Visonac, in parallel with ongoing partner search. The company will focus on its urology franchise and its continued commitment to driving growth, particularly in the United